AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22938002 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme preparations (EXD and EXN)
Number of subjects: 0
Study 19574870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular block
Number of subjects: 232
Study 19574870 — intervention group
Group type: COMPARATOR
Intervention: Transarterial axillary block
Number of subjects: 232
Study 17616840 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, group-based, moderate-intensity walking program (n = 77)
Number of subjects: 155
Study 17616840 — intervention group
Group type: COMPARATOR
Intervention: Daily vitamin B pills (n = 78)
Number of subjects: 155
Study 17616840 — intervention group
Group type: COMPARATOR
Intervention: Light-intensity placebo activity program (n = 75)
Number of subjects: 155
Study 17616840 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills (n = 74)
Number of subjects: 155
Study 14687958 — intervention group
Group type: COMPARATOR
Intervention: Standard drug treatment
Number of subjects: 0
Study 14687958 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced drug treatment (e.g. case management and added social services)
Number of subjects: 0
Study 11120398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg doses of pentagastrin
Number of subjects: 35
Study 11120398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 microg/kg doses of pentagastrin
Number of subjects: 35
Study 11120398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 microg/kg doses of pentagastrin
Number of subjects: 35
Study 11120398 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 microg/kg doses of pentagastrin
Number of subjects: 35
Study 11120398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9830263 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% butenafine and 20% urea cream
Number of subjects: 60
Study 9830263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9830263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 60
Study 9830263 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 60
Study 7540789 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% hydroxyethyl starch 120/0.7
Number of subjects: 60
Study 7540789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% dextran 70
Number of subjects: 60
Study 7540789 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 120/0.7
Number of subjects: 60
Study 7540789 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 60
Study 7540789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 2025524 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclosporine, prednisone, azathioprine)
Number of subjects: 0
Study 2025524 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (prednisone, azathioprine)
Number of subjects: 0
Study 6113483 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin (0.075 IU/kg)
Number of subjects: 0
Study 6113483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular insulin (0.075 IU/kg)
Number of subjects: 0
Study 6113483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (0.075 IU/kg)
Number of subjects: 0
Study 30621794 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive control training program (30 min daily, 5 days/week for 12 weeks)
Number of subjects: 70
Study 30621794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 70
Study 30621794 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive control training program
Number of subjects: 70
Study 28914250 — intervention group
Group type: COMPARATOR
Intervention: Pit and fissure sealant placed without bonding agent (GROUP A)
Number of subjects: 37
Study 28914250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following sixth generation bonding agent (ADPER PROMT) (GROUP B)
Number of subjects: 37
Study 28914250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following seventh generation bonding agent (OPTIBOND) (GROUP C)
Number of subjects: 37
Study 28914250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pit and fissure sealant placed following eighth generation bonding agent (FUTURA BOND DUAL CURE) (GROUP D)
Number of subjects: 37
Study 25886805 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (16 classes over 8 weeks)
Number of subjects: 57
Study 25886805 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 57
Study 25886805 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 57
Study 24427795 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalens HD single‐optic accommodating IOL
Number of subjects: 64
Study 24427795 — intervention group
Group type: COMPARATOR
Intervention: Tecnis ZCB00 aspheric monofocal IOL
Number of subjects: 64
Study 21338971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary pyloromyotomy (ICP)
Number of subjects: 40
Study 21338971 — intervention group
Group type: COMPARATOR
Intervention: Extracavitary pyloromyotomy (ECP)
Number of subjects: 40
Study 21338971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICP and ECP
Number of subjects: 40
Study 19723739 — intervention group
Group type: EXPERIMENTAL
Intervention: START program (short-term acute residential treatment)
Number of subjects: 93
Study 19723739 — intervention group
Group type: COMPARATOR
Intervention: Hospital psychiatric unit
Number of subjects: 93
Study 17428343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrilon Omneo (new formula; NF)
Number of subjects: 38
Study 17428343 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 38
Study 15065964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg, administered daily or targeted to high‐risk drinking situations
Number of subjects: 153
Study 15065964 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted administration of Naltrexone
Number of subjects: 153
Study 15065964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (targeted administration)
Number of subjects: 153
Study 15065964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 11557107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Number of subjects: 221
Study 11557107 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin 500 mg/m(2), mitomycin C 8 mg/m(2), vindesine 3 mg/m(2) per cycle
Number of subjects: 221
Study 11557107 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin arm
Number of subjects: 221
Study 9662230 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Bicycle Stress Echocardiography (SBSE)
Number of subjects: 20
Study 9662230 — intervention group
Group type: COMPARATOR
Intervention: Treadmill Testing
Number of subjects: 20
Study 7730842 — intervention group
Group type: EXPERIMENTAL
Intervention: General Well-Being Adjustment Scale (GWB)
Number of subjects: 545
Study 3190969 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain solution (0.5% bupivacaine 3 ml)
Number of subjects: 20
Study 3190969 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric solution (0.5% bupivacaine 3 ml)
Number of subjects: 20
Study 31655020 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 5482
Study 31655020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5482
Study 29231315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with regulating mind and spleen (6 weeks, applied at specific acupuncture points, 3 times a week).
Number of subjects: 81
Study 29231315 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium bromide tablet (50 mg, 3 times a day for 6 weeks).
Number of subjects: 81
Study 25252296 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral nicorandil
Number of subjects: 138
Study 25252296 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral nicorandil
Number of subjects: 138
Study 25252296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicorandil)
Number of subjects: 138
Study 24315282 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 84
Study 24315282 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 84
Study 24315282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritional sucking
Number of subjects: 84
Study 21184171 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood disorder
Number of subjects: 0
Study 21184171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of victimization
Number of subjects: 0
Study 21184171 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in neighborhood disorder
Number of subjects: 0
Study 18337343 — intervention group
Group type: EXPERIMENTAL
Intervention: AS + AQ (3 days)
Number of subjects: 0
Study 18337343 — intervention group
Group type: EXPERIMENTAL
Intervention: AS + SP (single dose)
Number of subjects: 0
Study 18337343 — intervention group
Group type: EXPERIMENTAL
Intervention: AS monotherapy (5 days)
Number of subjects: 0
Study 18337343 — intervention group
Group type: COMPARATOR
Intervention: AS + SP
Number of subjects: 0
Study 18337343 — intervention group
Group type: COMPARATOR
Intervention: AS + AQ
Number of subjects: 0
Study 17181919 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-PVP (2 ml, 3.4 mg of collagen)
Number of subjects: 30
Study 14677007 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament tape
Number of subjects: 100
Study 14677007 — intervention group
Group type: COMPARATOR
Intervention: Multifilament tape
Number of subjects: 100
Study 10632418 — intervention group
Group type: COMPARATOR
Intervention: CC (100 mg daily for 5 days)
Number of subjects: 64
Study 10632418 — intervention group
Group type: EXPERIMENTAL
Intervention: CC (100 mg daily for 5 days) plus ethinyl E2 (0.05 mg daily for 5 days)
Number of subjects: 64
Study 10632418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 64
Study 9187782 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml.kg‐1 Ringer's Lactate solution over 20 min (preload group, n = 10)
Number of subjects: 20
Study 9187782 — intervention group
Group type: COMPARATOR
Intervention: No crystalloid infusion (no‐preload group, n = 10)
Number of subjects: 20
Study 7903180 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 0
Study 3922395 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 16
Study 3922395 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine
Number of subjects: 16
Study 31687186 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim piezoelectric tips
Number of subjects: 20
Study 31687186 — intervention group
Group type: COMPARATOR
Intervention: Manual mini-five area-specific curets
Number of subjects: 20
Study 29098432 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoloop
Number of subjects: 120
Study 29098432 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler
Number of subjects: 120
Study 29098432 — intervention group
Group type: EXPERIMENTAL
Intervention: Hem-o-lok
Number of subjects: 120
Study 29098432 — intervention group
Group type: EXPERIMENTAL
Intervention: DS clips
Number of subjects: 120
Study 26595751 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 gauge needle
Number of subjects: 36
Study 26595751 — intervention group
Group type: COMPARATOR
Intervention: 23 gauge needle
Number of subjects: 36
Study 26595751 — intervention group
Group type: COMPARATOR
Intervention: 21 gauge needle
Number of subjects: 36
Study 24611636 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain foods rich in lignans (30 g/d of breakfast cereals or biscuits, 80 g/d of whole grain pasta)
Number of subjects: 13
Study 24611636 — intervention group
Group type: COMPARATOR
Intervention: Refined grain foods
Number of subjects: 13
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard fasting)
Number of subjects: 48
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (water)
Number of subjects: 48
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: CHO group (water with 50 g maltodextrine)
Number of subjects: 48
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: GLN group (water with 50 g maltodextrine plus 40 g GLN)
Number of subjects: 48
Study 22235107 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN group
Number of subjects: 48
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48
Study 22235107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 19996769 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extension training for 3 months
Number of subjects: 8
Study 19996769 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining period
Number of subjects: 8
Study 17708711 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 6, 14, or 30 mg every 3 months
Number of subjects: 412
Study 17708711 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 14, 60, 100, or 210 mg every 6 months
Number of subjects: 412
Study 17708711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 17708711 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 412
Study 16094663 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-225 mg/day)
Number of subjects: 16
Study 11965558 — intervention group
Group type: EXPERIMENTAL
Intervention: Color ultrasound imaging of the urethra
Number of subjects: 28
Study 9535245 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPtxd
Number of subjects: 3450
Study 9535245 — intervention group
Group type: COMPARATOR
Intervention: DT
Number of subjects: 3450
Study 7657849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicoderm
Number of subjects: 24
Study 7657849 — intervention group
Group type: COMPARATOR
Intervention: Habitrol
Number of subjects: 24
Study 2510652 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D+) group: 14 patients, receiving a loading dose of 0.3 mg/kg followed by a continuous IV infusion of 2 micrograms/kg/d, then orally (120-180 mg/d) throughout the study.
Number of subjects: 30
Study 2510652 — intervention group
Group type: COMPARATOR
Intervention: Control (D-) group: 16 patients, no diltiazem treatment.
Number of subjects: 30
Study 2510652 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D+) group: 14 patients.
Number of subjects: 30
Study 2510652 — intervention group
Group type: COMPARATOR
Intervention: Control (D-) group: 16 patients.
Number of subjects: 30
Study 29916944 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms (measured by validated self‐administered questionnaires)
Number of subjects: 121
Study 29916944 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety (measured by Spielberger Trait Anxiety)
Number of subjects: 121
Study 29916944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive anxiety (measured by HADS Anxiety Subscale)
Number of subjects: 121
Study 29916944 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured by HADS Depression Subscale and Beck Depression Inventory)
Number of subjects: 121
Study 27581434 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexyn2a (10 μg)
Number of subjects: 30
Study 27581434 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexyn2a with aluminum adjuvant
Number of subjects: 30
Study 27581434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25428164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling kit received by mail
Number of subjects: 3596
Study 25428164 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional container received by mail
Number of subjects: 3596
Study 25428164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling kit received at the clinic
Number of subjects: 3596
Study 25428164 — intervention group
Group type: COMPARATOR
Intervention: Conventional container received at the clinic
Number of subjects: 3596
Study 25428164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sampling kit and conventional container
Number of subjects: 3596
Study 21815994 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotome technique
Number of subjects: 30
Study 21815994 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 30
Study 21815994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study 20851942 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 131
Study 20851942 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 131
Study 18465341 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, and fluorouracil)
Number of subjects: 980
Study 18465341 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 980
Study 18465341 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A aberrations (amplifications and deletions)
Number of subjects: 980
Study 18465341 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A deletions
Number of subjects: 980
Study 18465341 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A amplifications
Number of subjects: 980
Study 17169794 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-dose methotrexate (33.6 g/m2)
Number of subjects: 484
Study 17169794 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-dose methotrexate (33.6 g/m2) with intensified systemic and intrathecal therapy
Number of subjects: 484
Study 17169794 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiation plus intrathecal methotrexate
Number of subjects: 484
Study 17169794 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methotrexate alone
Number of subjects: 484
Study 12668651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 2 weeks with filgrastim
Number of subjects: 2005
Study 12668651 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 2 weeks with filgrastim
Number of subjects: 2005
Study 12668651 — intervention group
Group type: COMPARATOR
Intervention: Sequential doxorubicin (A) x 4 -> paclitaxel (T) x 4 -> cyclophosphamide (C) x 4 every 3 weeks
Number of subjects: 2005
Study 12668651 — intervention group
Group type: COMPARATOR
Intervention: Concurrent doxorubicin and cyclophosphamide (AC) x 4 -> paclitaxel (T) x 4 every 3 weeks
Number of subjects: 2005
Study 10877376 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold‐related suprathreshold examination strategy
Number of subjects: 322
Study 10877376 — intervention group
Group type: COMPARATOR
Intervention: FASTPAC threshold central visual field examination strategy
Number of subjects: 322
Study 9088999 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxophylline 400 mg orally, 3 times daily
Number of subjects: 67
Study 8251249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-brush rinse containing 0.03% triclosan and 0.125% copolymer, rinsed twice daily for 6 months.
Number of subjects: 125
Study 8251249 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-brush rinse, rinsed twice daily for 6 months.
Number of subjects: 125
Study 3700197 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1 results made available to group A
Number of subjects: 146
Study 3700197 — intervention group
Group type: COMPARATOR
Intervention: HbA1 results withheld from group B
Number of subjects: 146
Study 3700197 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of HbA1 concentrations by physician and patient/parent
Number of subjects: 146
Study 3700197 — intervention group
Group type: COMPARATOR
Intervention: Patients with initial HbA1 less than 12.7%
Number of subjects: 146
Study 29858688 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g Arg/day
Number of subjects: 101
Study 29858688 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g Arg/day
Number of subjects: 101
Study 29858688 — intervention group
Group type: COMPARATOR
Intervention: 0 g Arg/day (placebo)
Number of subjects: 101
Study 29953191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 80 mg
Number of subjects: 370
Study 29953191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 81 mg
Number of subjects: 370
Study 29953191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg
Number of subjects: 370
Study 29953191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg
Number of subjects: 370
Study 29953191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IHD)
Number of subjects: 370
Study 24261900 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile traction therapy (PTT) for 6 months
Number of subjects: 55
Study 24261900 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NIG)
Number of subjects: 55
Study 22909281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 0.3 mg/kg stat
Number of subjects: 232
Study 22909281 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 1 mg/kg/day for three days
Number of subjects: 232
Study 20056845 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (14% O(2))
Number of subjects: 9
Study 20056845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnic hypoxia (14% O(2))
Number of subjects: 9
Study 20056845 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (21% O(2))
Number of subjects: 9
Study 20056845 — intervention group
Group type: COMPARATOR
Intervention: Isocapnic hyperoxia (40% O(2))
Number of subjects: 9
Study 18230747 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for OSAHS
Number of subjects: 0
Study 18230747 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of co-existent SDB
Number of subjects: 0
Study 16686082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral Medication Complexity Index (AMCI)
Number of subjects: 0
Study 14974733 — intervention group
Group type: EXPERIMENTAL
Intervention: Difructose anhydride III (DFAIII) - 10 g in a 200 mL water solution
Number of subjects: 9